Should be enough in the bank for the US market, seems like...

Should be enough in the bank for the US market, seems like they've already gained good traction there based on the growth they've recorded so far. Might look to raise again in a year or so to pursue an aggressive global expansion if they feel there's an opportunity there, although I would say the aim would be for the share price to be significantly higher by then on the back of continued strong growth in the US (so I'd say an opportunity rather than a risk). Should be enough to get them to cash flow positive in the US though.

There are a number of larger competitors, but as shown in the first post iTrack Advance complements those procedures very well. Doctors don't really need to decide which MIGS procedure is best like they do when deciding between which stent to use, it makes a lot of sense to go in with iTrack Advance first to flush out the entire drainage system, then implanting a stent for added results if needed. It is also quite differentiated, the only device that does not tear or leave a stent behind. Pretty important for patients in the earlier stage of the disease who may be hesitant about surgical intervention. Plenty of safety and efficacy data as well.

Key risks are the usual for most healthcare companies, mostly regulatory. Reimbursement was obviously threatened last year to be cut, but doctors, patients, companies, industry bodies and politicians rallied together in support of these procedures, resulting in the proposed changes being completely overturned. Whilst this highlighted the regulatory risk, the fact that the industry was so successful in pushing back this decision (very rare for a final LCD to be completely dropped) has definitely helped reduce the risk of something like this happening again. Much easier things for the insurers to target.